Neuroendocrinology
Generic version of injectable acromegaly treatment launches in US
A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release.
Once-monthly octreotide provides sustained acromegaly control with fewer injections
BOSTON — Adults with acromegaly previously controlled with standard of care experienced similar disease control with once-monthly injectable octreotide at 24 and 52 weeks, with no serious adverse events, data presented at ENDO 2024 show.
Oral medication lowers IGF-1 levels below upper limit of normal for most with acromegaly
More than half of adults with acromegaly receiving a novel once-daily oral medication achieved an insulin-like growth factor-1 level at or below the upper limit of normal, according to topline results from the PATHFNDR-2 trial.
High heterogeneity observed for baseline variables included in pituitary adenoma studies
Common data elements are needed to reduce heterogeneity in studies on transsphenoidal pituitary adenoma surgery, according to a systematic review published in Pituitary.
FDA grants breakthrough therapy designation for oral congenital adrenal hyperplasia drug
The FDA granted breakthrough therapy designation for an oral non-glucocorticoid medication for the treatment of congenital adrenal hyperplasia, according to an industry press release.
Oral acromegaly agent reduces IGF-1 levels below upper limit of normal for most adults
More than 80% of adults with acromegaly achieved an insulin-like growth factor level at or below the upper limit of normal at 36 weeks with an investigational once-daily oral medication, according to topline results from a phase 3 trial.
Most adults with acromegaly achieve normal IGF-I levels with long-acting pasireotide
More than half of adults with acromegaly receiving the somatostatin receptor ligand pasireotide achieved normal insulin-like growth factor I levels, according to data from a long-term real-world study.
Cushing’s syndrome treatment maintains reductions in urinary free cortisol for 12 months
Most adults with Cushing’s syndrome receiving levoketoconazole twice daily maintained reductions in mean urinary free cortisol levels during a 12-month maintenance period, according to findings from the SONICS study extended evaluation.
Endoscopic surgery confers higher acromegaly remission rate than microscopic surgery
Endoscopic transsphenoidal surgery has the best remission rates and fewest postoperative complications for adults with acromegaly, according to findings from a systematic review.
Oral octreotide efficacy maintained in more than 90% of adults with acromegaly at 3 years
ATLANTA — More than 90% of adults with acromegaly remained responders to oral octreotide 3 years after initiating treatment, according to findings from the MPOWERED open-label extension study presented at ENDO 2022.